奥希替尼联合司美替尼或西妥昔单抗双靶向EGFR在活化EGFR非小细胞肺癌模型中的抗肿瘤疗效
本研究在EGFR突变非小细胞肺癌(NSCLC)体内模型中评估奥希替尼联合MEK1/2抑制剂司美替尼或单克隆抗体西妥昔单抗的疗效。结果显示,二线治疗中联合方案使多数小鼠恢复对奥希替尼的敏感性,反应率50%-80%,中位无进展生存期(mPFS)28周;一线早期使用联合方案反应率提高至90%,mPFS未达到,显著优于奥希替尼单药(p<0.005)。耐药细胞中發現Hedgehog通路激活,SMO抑制剂联合奥希替尼和司美替尼可抑制耐药细胞增殖与迁移侵袭。
要点
- 奥希替尼联合司美替尼或西妥昔单抗在二线治疗中使多数小鼠恢复对奥希替尼的敏感性,反应率50%-80%。
- 一线早期使用联合方案反应率达90%,mPFS未达到,显著优于奥希替尼单药(p<0.005)。
- 耐药与Hedgehog通路激活及其与MAPK通路的相互作用相关。
核心结论
- 奥希替尼联合司美替尼或西妥昔单抗的双重垂直EGFR阻断是EGFR突变NSCLC的有效治疗选择。
- Hedgehog通路激活及其与MAPK通路的相互作用参与对联合治疗的耐药。
研究设计与样本
- 在HCC827(E746-A759del/T790M-)、H1975(L858R/T790M+)和PC9-T790M(E746-A759del/T790M+)异种移植瘤模型中评估奥希替尼联合司美替尼或西妥昔单抗的疗效。
- 在奥希替尼耐药后的二线治疗和一线治疗中分别评估联合方案。
- 探索耐药机制,包括从奥希替尼联合司美替尼耐药肿瘤中获得的离体原代细胞培养。
主要发现
- 二线治疗中联合方案使多数小鼠恢复对奥希替尼的敏感性,反应率50%-80%,一线加二线治疗的中位无进展生存期(mPFS)为28周。
- 一线治疗中联合方案将反应率提高至90%,三种异种移植瘤模型中所有联合治疗组的mPFS均未达到,与奥希替尼相比具有统计学显著优势(p<0.005),一线治疗中mPFS时间为17至18周。
- 在奥希替尼联合司美替尼耐药肿瘤的离体原代细胞培养中發現Hedgehog通路激活,SMO抑制剂联合奥希替尼和司美替尼可抑制耐药细胞的增殖、迁移和侵袭特性。
临床怎么用
- 对于EGFR突变NSCLC,奥希替尼联合司美替尼或西妥昔单抗的双重垂直EGFR阻断可能是一种新的有效治疗选项。
- 一线早期使用联合方案可能提高反应率并延长无进展生存期,但需进一步临床验证。
- 耐药后Hedgehog通路激活,联合SMO抑制剂可能克服耐药。
局限性
- 研究仅基于体内异种移植瘤模型和离体细胞培养,尚未在临床试验中验证。
- 样本量未在摘要中报告,统计效能有限。
- 耐药机制探索尚不全面,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models. METHODS: We evaluated combinations of osimertinib plus selumetinib/cetuximab in HCC827 (E746-A759del/T790M-), H1975 (L858R/T790M+), and PC9-T790M (E746-A759del /T790M+) xenografts in second-line therapy after the development of resistance to osimertinib, and in first-line therapy, and we explored mechanisms of resistance to these treatments. RESULTS: The addition of selumetinib or cetuximab to osimertinib in second-line therapy reverted the sensibility to osimertinib in the majority of mice, with a response rate (RR) of 50% to 80%, and a median progression-free survival (mPFS) of first- plus second-line of therapy of 28 weeks. The early use of combinations in first-line therapy increased the RR to 90%, with an mPFS not reached in all combination arms in the three xenografts models, with a statistically significant superiority (p < 0.005) as compared to osimertinib, achieving in first-line therapy an mPFS time of 17 to 18 weeks. Moreover, in ex vivo primary cell cultures obtained from osimertinib plus selumetinib-resistant tumors, we found Hedgehog pathway activation and we showed that therapy with an SMO inhibitor plus osimertinib and selumetinib inhibited proliferation and migratory and invasive properties of resistant cells. CONCLUSIONS: We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments.
引用
- Della Corte CM, Ciaramella V, Cardone C, et al. Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. J Thorac Oncol. 2018. PMID: 29526823. doi:10.1016/j.jtho.2018.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。